Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Subjects With Type 2 Diabetes to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PATAS

NCT07223333 is registered in ClinicalTrials.gov with AdipoPharma LLC as lead sponsor.

NCT NCT07223333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Subjects With Type 2 Diabetes to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PATAS
Lead sponsor
AdipoPharma LLC
Phase
Phase 1
Overall status
Recruiting
Start date
January 27, 2026
Completion date
May 30, 2027
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes